Table 1. Chemoradiotherapy regimens in randomized trials included in the meta-analysis.
| First author | Year | Sample size | Pathology | Neoadjuvant treatment schedule | ||
|---|---|---|---|---|---|---|
| NCRTS | SA | total | ||||
| Wlsh | 1996 | 58 | 55 | 113 | AC | Cis 75mg/m2 on days 7 and 42; FU 15 mg/kg on days 1-5 and 36-40 40 Gy in 15 fractions over 3weeks |
| Shapiro | 2015 | 178 | 188 | 366 | AC and SCC | Carboplatin (AUC 2 mg/mL per min) and paclitaxel (50 mg/m2 of body-surface area) were administered intravenously for five cycles, starting on days 1, 8, 15, 22, and 29. A total concurrent radiation dose of 41·4 Gy was given in 23 fractions of 1·8 Gy, on 5 days per week (excluding weekends), starting on the fi rst day of the first chemotherapy cycle. |
| Mariette | 2014 | 81 | 89 | 170 | AC and SCC | A total dose of 45 Gy was delivered in 25 fractions (five fractions per week) over 5 weeks. Chemotherapy was delivered concomitantly and composed of two cycles of fluorouracil (FU) and cisplatin. FU 800 mg/m2 per 24 hours was administered as a continuous infusion from days 1 to 4 and 29 to 32. Cisplatin 75mg/m2 was delivered by infusiononday 1 or 2 and againonday 29 or 30. |
| Lv | 2010 | 80 | 80 | 160 | SCC | Radiation was delivered in a total dose of 40 Gy (20 fractions at 2 Gy per fraction). For chemotherapy, 2 cycles were administered on days 1-3 and days 22-24 of radiotherapy. A paclitaxel (PTX)+cisplatin (DDP) regimen was used, including PTX (135 mg/m2 per day) administered as a short-term infusion on day 1 of each cycle, while DDP (20 mg/m2 per day) was delivered as a continuous infusion over 24 h on days 1-3 of each cycle. |
| Burmeister | 2005 | 128 | 128 | 256 | AC and SCC | Cis 80mg/m2 on day 1; FU 800 mg/m2 per day on days 1-4, 35 Gy in 15 fractions over 3 weeks |
| Cao | 2009 | 118 | 118 | 236 | SCC | Cis 20 mg/m2 per day on days 1–5; FU 500 mg/m2 per day on days 1–5; mitomycin 10mg/m2 per day on day 1 40 Gy, 2 Gy per fraction over 4weeks |
| Lee | 2004 | 51 | 50 | 101 | SCC | Cis 60 mg/m2 on days 1 and 22; FU 1000 mg/m2 per day on days 2–5. 45·6Gy, 1·2Gy per fraction over 28 days |
| Tepper | 2008 | 30 | 26 | 56 | AC and SCC | Cis 60mg/m2 on days 1 and 29; FU 1000 mg/m2 per day on days 1–4 and 29–32 50·4Gy, 1·8Gy per fraction over 5·6weeks |
| Natsugoe | 2006 | 22 | 23 | 45 | SCC | A total radiation dose of 40 Gy was applied, in 2-Gy fractions delivered 5 days/week for 4 weeks to the media stinum and neck. In the same period, intravenous chemotherapy was performed using cisplatin (7 mg over 2 h) and 5-fluorouracil (5-FU; 350 mg over 24 h). |
| Urba | 2007 | 50 | 50 | 100 | AC and SCC | Cis 20mg/m2 on days 1–5 and 17–21; FU 300 mg/m2 on days 1–21; vinblastine 1 mg/m2 on days 1–4 and 17–20 45 Gy, 1·5Gy per fraction over 3weeks |
| Hsu | 2013 | 46 | 38 | 84 | SCC | The chemotherapy regimen included 80 mg/m2 of cisplatin intravenously on day 1 followed by 600 mg/m2/day of 5-fluorouracil and 90 mg/m2/day of leucovorin given by continuous intravenous infusion on days 1–4, concurrent with 45.0–50.4 Gy of externalbeam radiation at 1.8–2.0 Gy per fraction. |
| Apinop | 1994 | 35 | 34 | 69 | SCC | Cis 100 mg/m2 on days 1 and 29; FU 1000 mg/m2 per day on days 1–4 and 29–32 40 Gy, 2 Gy per fraction over 4weeks |
NCRTS, neoadjuvant chemoradiotherapy followed by surgery; SA , surgery alone; SCC, squamous cell carcinoma; AC, adenocarcinoma; Cis, cisplatin; FU, fluorouracil